Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study
| Autor: | Helen Karlsson, Stefan Ljunggren, Maritha Marcusson-Ståhl, Anders Hovland, M. Mathisen, Knut Tore Lappegård, Karin Cederbrant, Christian Abendstein Kjellmo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Lipoproteins Pilot Projects Familial hypercholesterolemia 030204 cardiovascular system & hematology Antibodies Monoclonal Humanized Lipoprotein particle Hyperlipoproteinemia Type II 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Lipoprotein apheresis Internal medicine medicine Humans Lipoprotein particles Cholesterol PCSK9-inhibition PCSK9 PCSK9 Inhibitors Serum amyloid A1 Klinisk medicin Antibodies Monoclonal Hematology Middle Aged medicine.disease Evolocumab 030104 developmental biology Endocrinology Apheresis chemistry Blood Component Removal Female lipids (amino acids peptides and proteins) Clinical Medicine LDL&HIPHEN Lipoprotein |
| Popis: | Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are last therapeutic resorts in patients with familial hypercholesterolemia (FH). We explored changes in lipoprotein subclasses and high-density lipoprotein (HDL) function when changing treatment from lipoprotein apheresis to PCSK9 inhibition. We measured the levels of low-density lipoprotein (LDL) and HDL particle subclasses, serum amyloid A1 (SAA1), paraoxonase-1 (PON1) activity and cholesterol efflux capacity (CEC) in three heterozygous FH patients. Concentrations of all LDL particle subclasses were reduced during apheresis (large 68.0 ± 17.5 to 16.3 ± 2.1 mg/dL, (p = 0.03), intermediate 38.3 ± 0.6 to 5.0 ± 3.5 mg/dL (p = 0.004) and small 5.0 ± 2.6 to 0.2 ± 0.1 mg/dL (p = 0.08)). There were non-significant reductions in the LDL subclasses during evolocumab treatment. There were non-significant reductions in subclasses of HDL particles during apheresis, and no changes during evolocumab treatment. CEC was unchanged throughout the study, while the SAA1/PON1 ratio was unchanged during apheresis but decreased during evolocumab treatment. In conclusion, there were significant reductions in large and intermediate size LDL particles during apheresis, and a non-significant reduction in small LDL particles. There were only non-significant reductions in the LDL subclasses during evolocumab treatment. Funding agencies: Amgen, Norway |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|